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ABSTRACT  
Sickle cell disease is an autosomal recessive genetic red cell disorder with 
worldwide distribution. Growing evidence suggests a possible involvement of 
complement activation in the severity of sickle cell clinical complication. Here, we 
found activation of the alternative complement pathway with microvascular 
deposition of C5b-9 on skin biopsies from sickle cell disease patients. This was also 
supported by sickle red cell membrane the deposition of C3b on sickle red cell 
membranes, which is locally promoted by the exposure of phosphatidylserine. In 
addition, we showed for the first time a peculiar “stop-and-go” motion of SCD RBCs 
on TNF-α activated vascular endothelial surfaces. 
Using the C3b/iC3b binding plasma protein Factor-H as an inhibitor of C3b cell-cell 
interactions, we found that Factor-H and Factor-H 19-20 domains prevent the 
adhesion of sickle red cells to the endothelium, normalizing speed transition times of 
red cells on inflammatory activated endothelium. We have firstly documented that FH 
acts by preventing the adhesion of sickle red cells to P-selectin and/or the receptor 
Mac-1 receptor (CD11b/CD18), supporting the activation of the alternative pathway 
of complement as an additional mechanism in the pathogenesis of acute sickle cell 
related vaso-occlusive crisis. Our data provide a rationale for further investigation of 
the potential contribution of Factor-H and other modulators of the alternative 
complement pathway with potential implications to the treatment of sickle cell 
disease.  
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INTRODUCTION 
Sickle cell disease (SCD; OMIM # 603903) is an autosomal recessive genetic 
red blood cell (RBC) disorder with worldwide distribution. SCD results from a point 
mutation (βS, 6V) in codon 6 of the β-globin gene where the insertion of valine in 
place of glutamic acid leads to the production of a defective form of hemoglobin, 
termed hemoglobin S (HbS) (1-3). Pathophysiological studies have shown that 
intravascular sickling in capillaries and small vessels leads to vaso-occlusion and 
impaired blood flow. Vaso-occlusive events in the microcirculation result from a 
complex and only partially known scenario involving the interactions between 
different cell types. These cells include dense, dehydrated sickle cells, reticulocytes, 
abnormally activated endothelial cells, leukocytes and platelets.(1-4) Plasma factors 
such as coagulation system cytokines and oxidized pro-inflammatory lipids may also 
be involved. In addition, the cyclic polymerization-depolymerization events promote 
RBC membrane oxidation and reduce RBC survival in the peripheral circulation(1, 5, 
6). The resulting increase in free hemoglobin and free heme, a consequence of the 
saturation of the physiologic system and local reduction of nitric oxide bioavailability, 
leads to a pro-coagulant state with increased risk of thrombotic events (2, 3, 7-10). 
All this evidence indicates that sickle cell vasculopathy is a crucial player in RBC 
adhesion events and in the generation of acute vaso-occlusive events in SCD 
patients.  
Although progress has been made in recent decades concerning the 
pathogenesis of SCD, the molecular events involved in these processes are still only 
partially delineated. Whereas, a key role for complement activation has been 
highlighted in chronic inflammatory processes characterized by hemolysis and 
inflammatory vasculopathy such as atypical hemolytic uremic syndromes (aHUS) 
and paroxysmal nocturnal hemoglobinuria (PNH) (11-14), the involvement of 
complement in SCD has been less extensively explored. Previous studies have 
revealed (i) an activation of the alternative complement pathway (AP) of complement 
activation in SCD patients; (ii) a reduction in the activating proteases factor B and D, 
modulating complement activation; (iii) a decrease in the plasma levels of FH, the 
major soluble regulator of AP activation; and (iv) increased deposition of the 
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complement opsonin C3b on RBC exposing phosphatidylserine (PS) (15-22). 
Preliminary data from a mouse model for SCD suggest a possible role for 
complement activation in the generation of vaso-occlusive crisis (VOCs), as an 
additional disease mechanism contributing to the severity of acute clinical 
manifestations related to SCD (23, 24).   
Because of its potential detrimental effects on host cells, the AP is finely 
regulated by membrane-bound and soluble regulators. Circulating FH plays a 
particularly important role, since this regulator not only binds to C3b and prevents the 
formation of C3b convertases, but it is also able to recognize self-associated 
molecular patterns such as sialic acid and glycosaminoglycans present on the 
membranes of most healthy cells (25-27). Any interference with this recognition 
process, resulting from either polymorphisms or blocking antibodies against FH, may 
have severe pathological consequences as described for aHUS and other 
complement mediated disorders (28).  
Here, we found that sickle RBCs are characterized by membrane deposition 
of C3b, which acts as a marker for the activation of the AP on sickle RBCs. We 
sought to determine whether C3b depositions on RBCs might possibly stimulate 
VOCs by favoring cell-cell interactions. Indeed, we now demonstrate for the first time 
a peculiar ex vivo motion profile (“stop-and-go” behavior) of SCD red cells during 
their transit on vascular endothelial surfaces, a motion that prolongs their transit of 
the vascular endothelial surface and promotes the adhesion of sickle RBCs. We 
show that FH and its 19-20 domain (29, 30),  which primarily targets C3b, prevent 
the adhesion of sickle RBCs to the endothelium. We further documented that FH 
acts by preventing the adhesion of sickle RBCs to P-selectin and/or the receptor 
Mac-1(CD11b/CD18). Our data provide a rationale for further investigation of FH and 
other modulators of the alternative complement pathway as novel disease modifying 
molecules with potential implications for the treatment of the clinical manifestations 
of SCD.  
 
METHODS 
Study design  
We studied SCD subjects (n=29; 26 SS and 3 Sβ0) subjects referred to the 
Department of Medicine, University of Verona and Azienda Ospedaliera Integrata of 
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Verona (Italy), from January 2012 to January 2017. SCD patients were evaluated at 
steady state, and none of them had been on either on hydroxyurea or a transfusion 
regimen during the 6 months immediately prior to our analysis. Healthy controls were 
matched by age, sex and ethnic background. The study was approved by the Ethical 
Committee of the Azienda Ospedaliera Integrata of Verona (Italy) and informed 
consent was obtained from patients and healthy controls (Ethical approval 
FGRF13IT). Table 1 shows the demographic characteristics of both the healthy and 
SCD subjects studied. Biochemical and hematologic parameters as well as plasma 
levels of C3 and C4 were determined according to clinical and laboratory standards 
at the Laboratory of Medicine, University of Verona and Azienda Ospedaliera 
Integrata of Verona (Italy).  Plasma C5a (EIA Quidel Corp., San Diego, CA; USA), 
plasma VCAM-1 (Invitrogen, Carlsbad, CA; USA) and serum FH (Hycult Biotech, 
Uden, The Netherlands) were determined by ELISA, according to manufacturers’ 
protocols (31).  
Evaluation of C5b-9 complement deposition on fixed skin biopsy 
Skin punch biopsies were carried out on the volar surface of the left arm on 
apparently normal skin. The samples were paraffin-embedded and examined by 
routine hematoxylin and eosin (H and E); they also were used to estimate the 
presence, within the microvasculature (32). Details on Immunofluorescent and 
Immunohistochemical staining assays are reported in Supplemental Methods (32-
34).  
 Measurements of phosphatidylserine+ and C3d+ RBCs 
Phosphatidylserine (PS)-positive cells were detected as previously reported 
(35-37). Details are reported in Supplemental Methods.  
RBCs adhesion assay 
The real time adhesion of RBCs collected from healthy and SCD subjects on 
inactive or activated endothelium (in the absence or presence of TNF-α, 
respectively) was performed as previously reported (38-40) with or without FH or 
FH19-20 or FH68 domains (41). Details are reported in Supplemental Methods.  
Development of an algorithm to determine RBC transit and flux trajectory 
Details on the algorithm to determine RBC transit and flux trajectory are 
reported in Supplemental Methods. 
P-selectin and Mac-1 expression in vitro in vascular endothelial cells  
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Details on immunoblot (42) and cytofluorimetric analysis are reported on 
Supplemental Methods.  
Statistical analysis 
All calculations were performed using the IBM SPSS 20.0 (IBM Inc., Armonk, 
NY) statistical package. The level of aggregation was expressed as median values 
with the minimum-maximum range and shown by means of either dot or box plots. 
Data were analyzed with non-parametric tests, the Mann-Whitney U test for unpaired 
samples and Wilcoxon signed-rank test for paired samples. A value of P<0.05 was 
considered statistically significant.  
 
RESULTS  
SCD patients show activation of the AP and increased C3d+ RBCs 
Untreated SCD subjects at steady state were studied. As shown in Table 1, 
reduced hemoglobin, increased reticulocyte counts and plasma LDH, all signs of 
chronic hemolytic anemia were observed (Table 1). In SCD patients, we also found a 
significant increase of plasma CRP and sVCAM-1 levels, indicating the presence of 
chronic inflammatory vasculopathy in agreement with previous reports (2, 3, 9, 43). 
Serum C3 and C4 were similar in healthy and SCD subjects (data not shown); 
whereas levels of the complement activation fragment C5a were significantly 
elevated in SCD patients when compared to healthy individuals (Fig. 1A); statistical 
analyses were performed to exclude the possible contribution of confounding factors 
such as gender or smoking status. Our finding is consistent with previous reports, 
and confirms the substantial complement activation in SCD patients, likely via the AP 
(15-22).    
Since studies in aHUS have shown that skin biopsy might be a feasible tool 
for documenting AP activation by C5b-9 vascular deposition (32),  we obtained skin 
biopsies from SCD patients at steady state. We considered skin to be an interesting 
window of observation in SCD, since (i) it might be involved in clinical manifestation 
of SCD, such as leg ulcers; and (ii) it has been widely used in SCD mouse models to 
functionally characterize the microvasculature (44-47). As shown in Fig. 1B, we 
observed microvascular intense, focal granular deposition of C5b-9 in small vessels 
throughout the dermis of SCD patients. This pattern is similar to that reported in skin 
biopsies from patients with aHUS, which is a thrombotic microangiopathy related to 
complement dysfunction (32). No deposition of C5b9 was observed in skin from 
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healthy controls (Fig. 1SA-B). Co-localization of C59b deposits and CD31-positive 
skin vessels was confirmed by immunohistochemical staining only in the skin 
biopsies from SCD patients (Fig. 1C, Fig. 2SA-B).   
Taken together, our data indicate an activation of AP in SCD, with possible 
involvement of complement in SCD vasculopathy and in related cellular adhesion 
events.  
To understand whether AP activation occurs directly on sickle RBCs, we 
measured the amounts of circulating RBCs carrying C3-derived opsonins by 
detecting the presence of the common C3d fragment (11, 12). As shown in Fig. 1D, 
higher amounts of C3d+ RBC were found in SCD patients in the steady state when 
compared to healthy subjects (representative scatter-plots are shown in Fig. 3S). 
This fraction further increased in a subgroup of SCD patients during acute pain crisis 
(SS steady state 2.5+0.8% vs SS pain-crisis: 6.1+0.7 % P<0.02; n=10), in 
agreement with an observation by Mold et al. (18). Since a previous report has linked 
the activation of AP with deposition of C3 opsonins to the exposure of PS on SCD 
RBC surfaces, we evaluated the percentage of PS+ RBCs in our SCD patients (17). 
Indeed, we found increased percentage of PS+ RBCs in SCD patients compared to 
healthy subjects in agreement with previous studies (35, 36) (Fig. 1E). In contrast to 
PNH, in which opsonization leads to rapid lysis of affected RBCs (11, 12), the 
presence of functional membrane regulators on SCD erythrocytes allowed a low 
level of C3-fragment deposition, which might also be considered as marker of 
complement activation on sickle RBCs. We therefore reasoned that the presence of 
C3b, iC3b or C3dg may function as a site of adhesion of SCD RBCs to activated 
vascular endothelial surface, which may carry ligands for C3 fragments, such as 
Mac-1 or P-selectin (48, 49). To study this event, we used the C3b and iC3b binding 
plasma protein FH as an inhibitor (25-27) and saw no significant differences in FH 
serum levels (AA median: 841 (range 616-1528) µg/mL vs SCD median: 980 (741-
1301) µg/mL; NS) between healthy and SCD subjects.    
 
FH prevents the adhesion of sickle RBCs to TNF-α activated vascular 
endothelium  
We performed an ex vivo adhesion assay using TNF-α- activated vascular 
endothelial cells and monitored in real time the adhesion of RBCs collected from 
healthy and SCD subjects to inactive (no TNF-α) or activated endothelium (plus 
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TNF-α) as previously described (38-40). Consistent with the literature, we observed 
significantly increased adhesion of SCD RBCs to TNF-α-activated endothelium when 
compared to normal RBCs (Fig. 2A, online video 1). We next investigated the effect 
of FH on the adhesion of healthy or SCD RBCs to activated vascular endothelium. 
The dose-response curve with FH showed a significant reduction in RBC adhesion at 
concentrations > 9 nM (Fig. 2B). This was more pronounced in SCD RBCs 
compared to healthy RBCs (Fig. 2B). Therefore, we expanded the tests to include a 
larger number of SCD patients using FH concentrations of 9 or 18 nM; as expected, 
reduced adhesion of SCD RBCs to the vascular endothelium was observed in 
presence of either 9 nM or 18 nM FH (Fig. 3A). Previous studies have identified two 
major regions on FH (i.e., domains 6-8 and 19-20) as the putative sites of interaction 
with the cell surface constituents such as glycosaminoglycans; furthermore, domains 
19-20 are also responsible for binding to sialic acids or C3d-containing deposits (29). 
We therefore evaluated whether any of these segments would have activity similar to 
that of full-length FH. 
Perfusion experiments performed on TNF-α-activated endothelium 
demonstrated that, like intact FH, FH19-20 (18 nM) strongly prevented the adhesion 
of sickle RBCs to the surface of TNF-α-activated vascular endothelium. Conversely, 
FH6-8 showed a trend toward a reduction in RBC adhesion that did not reach 
statistical significance (Fig. 3B). Our data indicate that the FH prevents sickle cell 
adhesion to the activated endothelium through its interaction with cell-surface sialic 
acids and C3b/iC3b found on the surface of pathological RBCs (Fig. 3B). 
 
FH and the FH19-20 domain normalize the sickle RBC trajectory and 
transverse velocity on TNF-α activated vascular endothelium 
 We then developed a new algorithm for RBCs to analyze their trajectory and 
transverse velocity, the velocity component perpendicular to the flow direction of the 
RBCs during their transit in the flowing chamber. The trajectory of each sickle RBC 
appeared irregular in space and was not uniform in time, especially when compared 
to that of healthy RBCs (Fig. 4A, B). This observation was based on the high 
transverse displacement and the presence of frequent stop-and-go motion that 
characterized the sickle RBCs transit of the activated vascular endothelium. The 
transverse velocity is a parameter that is correlated with the disturbed movement of 
a particle. Therefore, the path of healthy RBCs appears to be more regular, uniform, 
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and parallel to the flow (Fig. 4A, online video 2). Thus, healthy RBCs crossed the 
field of view more rapidly than did sickle RBCs (0.8-1.2 vs 1.7-2 sec, respectively; 
p<0.05). In the presence of FH, sickle RBCs regularized their trajectory (Fig. 4C), 
reducing their transverse velocity up to 7.71 ± 6.7 µm/second (average decrease of 
81.13% vs vehicle-treated sickle RBCs). The same behavior appeared in sickle 
RBCs treated only with the FH 19-20 domain alone (Fig. 4D), with the transverse 
speed being 6.56 ± 5.6 µm/second (an average decrease of 83.94% vs vehicle-
treated sickle RBCs). When the particle kinematics were quantified (Fig. 3E), we 
found that sickle RBCs exhibited an absolute value for the instantaneous transverse 
speed of 40.86 ± 27.6 µm/second, whereas for healthy cells the value was only 5.64 
± 4.9 µm/second (a difference of 86.20%). When healthy cells were compared to 
either FH or FH19-20-treated sickle RBCs, the absolute values for instantaneous 
transverse speed decreased significantly, reaching values similar to those observed 
for healthy RBCs.  
 
Anti-P-selectin and anti-Mac-1 antibodies prevent adhesion of SCD RBCs to 
TNF-α activated vascular endothelial surface  
 To better understand the possible binding proteins that are important for 
adhesion of C3b/iC3b+ SCD red cells, we then evaluated the effects of anti-P-
selectin antibody or anti-Mac-1 antibodies on the adhesion of SCD to TNF-α 
activated vascular endothelium. We chose these two molecules for the following 
reasons: (i) they are both modulated in endothelial cells (2, 50-55); (ii) P-selectin has 
been reported to bind C3b present on the membranes of circulating cells such as 
platelets (56); and (iii) Mac-1 is a well-known receptor for iC3b, and potentially C3dg 
associated with the cell membrane (25). In addition, P-selectin has been reported to 
bind RBCs, targeting red cell plasma-membrane sialic acid, whereas the presence of 
a Mac-1 binding site on RBC membranes is still under investigation (29, 48, 51, 57). 
In our model, the expression of P-selectin and Mac-1 was significantly increased in 
TNF-α activated vascular endothelium when compared to vehicle treated cells (Fig. 
4SA). Both anti-P-selectin and anti-Mac1 antibodies prevented the adhesion of sickle 
RBCs to the activated vascular endothelium (Fig. 5A). Whereas, the effect of the 
anti-P-selectin Ab on RBC adhesion may be mediated through an interference with 
two different targets (i.e., iC3b and/or sialic acid), the interplay between Mac-1 and 
iC3b deposited on sickle RBCs is considered to be more selective (25, 58). The anti-
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adhesive effect of the anti-Mac-1 Ab was more pronounced than that of the anti-P-
selectin Ab, but the difference was not statistically significant. No effect on the 
adhesion of sickle RBCs was documented in presence of a control Ab (Fig. 4SB). 
Collectively, these findings indicate that C3b/iC3b is deposited on sickle RBC 
membranes as a new ligand, bridging sickle RBCs to the activated vascular 
endothelial surface through binding to the pro-adhesive molecules: P-selectin and/or 
Mac-1.   
 
 
DISCUSSION 
Here, we confirm the activation of AP in SCD and we demonstrate, for the first 
time, cutaneous vascular deposition of C5b-9, supporting the involvement of 
complement in the microvascular injury associated with SCD.  
We then show that the activation of the AP results in C3 split-fragments being 
bound to the sickle RBC surface, thereby contributing to the adhesion of RBCs to the 
inflammatory activated vascular endothelial surface. Notably, decoration of 
erythrocytes with C3 opsonins was more evident in patients undergoing VOCs, 
further supporting the involvement of complement in microvascular injury in SCD. 
Since sickle RBCs, in contrast to PNH RBCs, still contain the functional complement 
regulators CD55 and CD59, PS-mediated complement activation may allow for a 
certain degree of opsonization without inducing hemolysis. This situation would lead 
to the observed accumulation of C3d-containing opsonins (i.e., C3b, iC3b, C3dg), 
which have all been associated with cell interaction and signaling functions (59). 
Thus, we propose that C3 split-fragments on RBCs might favor cell-cell interaction, 
as supported by previous observations of reduced RBCs-cells interactions in mice 
genetically lacking the C3 complement fraction (51, 60).   
We also demonstrate here that FH prevents the adhesion of sickle RBCs and 
normalizes their trajectory and tranverse velocity of sickle erythrocytes on TNF-α-
activated vascular endothelial surfaces through a mechanism involving P-selectin 
and/or Mac-1 as pro-adhesion molecule(s).  FH that binds to C3b/iC3b molecules 
present on cell surfaces and inhibits ACP. The algorithm developed within the 
present study allowed us to go farther in describing RBC adhesion to the endothelial 
surface. Indeed, we show that SCD RBCs adhere to endothelial cells with a peculiar 
dynamic behavior not shown by healthy RBCs. The stop-and-go profile of sickle 
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RBCs contributes to their irregular trajectory of sickle RBCs during their transit on the 
vascular endothelial surface. This slow and irregular movement clearly affects the 
speed transition time of sickle RBCs when compared to healthy controls, possibly 
contributing to the reduction in blood flow in the microcirculation that generally 
characterizes the early phase of acute VOCs (1, 5, 61-63). It is thus conceivable that 
our flow-based methodology could have a positive impact on the monitoring therapy 
of SCD. Both FH and its FH19-20 segment normalized the transit of sickle RBCs 
across the TNF-α activated vascular endothelial surface, abolishing the “stop-and-
go” behavior of sickle RBCs. This effect is of great importance because the transition 
time of sickle RBCs in microcirculation is critically related to the HbS polymerization 
time and the generation of dense, dehydrated RBCs, which contribute to the 
development of the acute clinical manifestation of SCD (1, 10). It is important to note 
that FH appears to exert a non-canonical function in preventing cell adhesion. This 
complement regulator typically inhibits complement activation via the AP by 
accelerating the decay of C3 convertases and by mediating the degradation of C3b 
to iC3b and C3dg via the plasma protease Factor I. Since our experiments have 
been performed using purified cells in the absence of plasma or serum, Factor I and 
the components involved in convertase formation cannot be involved in the observed 
effects. Rather, FH appears to interfere directly with cell-cell interaction events 
between sickle RBCs and endothelial cells.  
To further identify the mechanism of complement opsonin-mediated adhesion 
and the role of FH as an anti-adhesive molecule for SCD RBCs, we pre-coated 
vascular endothelial cells with either anti-P-selectin or anti-Mac-1 Abs. Both surface 
molecules are expressed on activated vascular endothelial cells and have been 
associated with opsonin interactions. Mac-1 is well-established as a functionally 
important receptor for iC3b that contributes to phagocytosis and cell activation. 
Whereas, the interplay of complement with P-selectin is less well described, several 
reports showed interactions between C3b and P-selectin (56, 64, 65). We found that 
the adhesion of sickle RBCs could be prevented by either anti-P-selectin or anti-
Mac-1 antibody, indicating that both molecules contribute to the adhesion of sickle 
RBCs to the vascular endothelium. In our studies, blocking Mac-1 had a more 
pronounced effect on adhesion than did impairing P-selectin activity. The beneficial 
impact of interfering with Mac-1 in SCD has been supported by the reduction of 
RBC-neutrophil interaction in SCD mice treated with anti-Mac-1 Ab(51) or in Mac-1-
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deficient SCD mice (57). Thus, our data indicates that complement is involved in the 
interaction between sickle RBCs and the endothelium, pointing to a new additional 
mechanism contributing to the biocomplexity of acute events in SCD.  
Our study therefore has potential implications for the clinical management of 
SCD. Current treatments in development are focused on the role of selectins in SCD 
pathology. For example, the anti-P-selectin antibody (crizanlizumab) that has been 
used to treat SCD and it has been reported to affect the length of time between 
acute pain-crisis in SCD patients (52, 66, 67). Similarly, the small molecule-based 
pan-selectin inhibitor, rivipansel, currently undergoing phase 3 clinical trials, is able 
to reduce the time required to resolve vaso-occlusive crises with a reduction in opioid 
treatment (68). Our findings suggest that targeting complement opsonization and/or 
opsonin-mediated cell adhesion could provide an alternative strategy. Whereas, the 
use of exogenous full-length FH as a therapeutic tool is associated with some 
challenges for being used as a therapeutic, several smaller variants of the regulator 
have shown promise in preclinical trials for complement-mediated diseases such as 
PNH. Owing to the importance of FH domains 19-20 for interfering with RBC 
adhesion, mini-FH constructs containing this domain pair may be considered, since 
they may affect both AP activity and the adhesive function of existing opsonins (69, 
70).  Alternatively, blocking opsonization itself at the level of C3 activation is also 
expected to impair complement-mediated adhesion. 
In conclusion, we have firstly shown that complement activation on sickle 
RBCs participates in the adhesion of sickle erythrocytes to the TNF-α activated 
vascular endothelium (Fig. 5B).  We have further demonstrated that the FH19-20 
segment is as efficient as FH in preventing the adhesion of sickle RBCs, and results 
in a normalization of sickle RBC transit across the vascular endothelial surface. We 
suggest that chronic hemolysis may require high levels of FH to prevent RBC 
adhesion and entrapment into microcirculation. Finally, our data indicate that FH 
might act as multimodal molecule, preventing the opsonization of sickle RBCs with 
C3 opsonins and targeting the interaction of sickle RBCs interaction with the 
endothelium through the adhesion molecules P-selectin and Mac-1 (Fig. 5B). Our 
findings provide a rationale for considering FH-based inhibitors and other modulators 
of the alternative complement pathway as potential new therapeutic options in SCD.  
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Table 1. Demographic, hematologic and biochemical data for healthy 
subjects and SCD patients  
  
Parameters Healthy Subjects 
 (n= 29) 
SCD Patients 
(n=29) 
Age (yr) 30.0 (25.0-42.5) 20.0 (17.0-47.0)∗ 
Gender (M/F) (n) 11/18 10/19 
Smokers (%) 10.3% (3) 6.8% (2) 
Systolic blood pressure (mmHg) 120 (110-130) 120 (112-130) 
Dyastolic blood pressure (mmHg) 65 (58-77) 64 (60-76) 
Hb (g/dL) 13.4 (12.5) 8.5 (8-9.5) * 
HbF (%) 2 (1.8-2.1) 4.5 (2.5-7.6) * 
Reticulocytes (cells * 103/uL) 44.6 ±12 250 ±27* 
White blood cells (109 cells/μL) 4.5 (3.8-5.2) 10.2 (8.8-11.9) 
Creatinine (mg/dL) 0.8 (0.7-1.0) 0.7 (0.3-1.5) 
LDH (U/L) 325.0 (261.5-413.0) 484.0 (310.2-1104.2) ∗ 
Albumin (g/L) 42.3 (39.2-46.7) 44.3 (35.6-49.7) 
CRP (mg/L) 0.9 (0.2-12.4) 3.0 (1.0-15.8) ∗ 
sVCAM-1 (pg/mL) 280 ±14 820±36* 
Yr: year; M: male; F: female; Hb: hemoglobin; HbF: fetal hemoglobin; LDH: lactate dehydrogenase; CRP: C 
reactive protein; sVCAM-1: serum vascular adhesion molecule-1. Ranges are shown in parentheses. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 19
 
 
 
 
FIGURE LEGENDS 
 
Fig. 1. The adhesion of C3d+ sickle RBCs is prevented by Factor H. (A) Healthy 
control (AA) and sickle cell (SCD) plasma samples were tested by ELISA assay (see 
Methods section); *p<0.05 AA vs SCD; n=10 in each group. (B) Deposition of C5b-9 
(orange fluorescence) assessed by immunofluorescent staining involving the 
abluminal aspect of the microvasculature in apparently normal skin of an SCD 
patient (direct immunofluorescence; original magnification x100). Inset. Detail of the 
vessels showing intense granular deposition of C5b9; direct immunofluorescence; 
original magnification: x 400. Nuclei were stained with Prolong Gold antifade reagent 
with DAPI (blue fluorescence).  The image shown is one representative image of 
other 16 with similar results. Lower panel. The percentage of vessels positive (+) for 
C5b9 granular deposition in skin biopsies from healthy (AA) and sickle cell patients 
(SCD). Data are shown as means±SD **p<0.002 AA vs SCD. (C) Left panel. 
Representative immunohistochemical image of a normal skin biopsy from SCD 
patient, showing a small vessel in the superficial dermis (arrow) characterized by co-
expression of C5b9 (brown) and CD31 (red); for comparison a C5b9 negative vessel 
(circle) only decorated with CD31 staining (red) is highlighted. One representative 
image is shown; all 16 gave similar results (n=16). Right panel. Quantification of 
C5b9 positive vessels in skin biopsies from health (see Fig. 2S) and SCD patients. 
Data are shown as means ±SD; **p<0.01 AA vs SCD.  
(D) Percentage of C3d positive red cell (red blood cells, RBCs) (C3d+) in healthy 
donor (AA) and in sickle cell subjects (n=16 AA; n=16 SCD). The dashed line 
indicates the threshold of normality, corresponding to C3d+ <0.5 % of RBCs; 
*p<0.05 AA vs SCD; ** p < 0.01 AA vs SCD. (E) Percentage of phosphatydylserine 
(PS) positive red cell (red blood cells, RBCs) (PS+) in healthy donor (AA) and in 
sickle cell subjects (n=20 AA; n=32 SCD). The dashed line indicates the threshold of 
normality, corresponding to C3b+ <0.5 % of RBCs; ** p < 0.01 AA vs SCD.  
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Fig. 2. (A) Healthy (AA) or sickle cell (SCD) RBC adhesion on immortalized 
endothelium (EA926.hy) treated with or without TNF-α under flow conditions (data 
are expressed as cells/mm2). Data are obtained from six separate comparable 
experiments. All calculations were performed using the IBM SPSS 20.0 (IBM Inc., 
Armonk, NY) statistical package. Adhesion tests are expressed as median values 
with the minimum-maximum range and shown by means of box plots. Data are 
analyzed with non-parametric tests, Mann-Whitney U test for unpaired samples and 
Wilcoxon signed-rank test for paired samples. A value of P<0.05 is considered 
statistically significant. (B) Dose-response curve for factor H (FH) in adhesion assay 
for healthy (AA) or sickle (SCD) red blood cells (RBCs). Data were obtained at 6 min 
flux on endothelium treated with either vehicle or TNF-α. The curve is representative 
of six separated and independent experiments with similar results. 
  
Fig. 3. FH and FH19-20 segment normalized the transit of sickle RBCs on TNF-
α activated vascular endothelial surface. (A) Sickle cell adhesion after 6 minutes 
of perfusion on activated or non-activated endothelium (+/- TNF-α) in the presence of 
FH 9 nM or 18nM final concentration. The data shown are representative of other six 
independent assays with similar results (n=6). Wilcoxon test: * indicates the 
corresponding significance. A value of p<0.05 was considered statistically significant. 
Statistical analysis as in Fig. 2A. (B) Sickle cell adhesion after 6 minutes of perfusion 
on activated or non-activated endothelium (+/- TNF-α) in presence of FH and its 
fragments 19-20 e 6-8 (18nM final concentration). Data shown are representative of 
other 6 independent assays with similar results (n=6). A value of p<0.05 was 
considered statistically significant. Statistical analysis as in Fig. 2A.  
 
Fig. 4. FH and FH 19-20 fragment normalized the “stop-and-go” motion of 
sickle RBCs. (A) Trajectory of three representative healthy RBCs in the field of 
view: each coordinate indicates their centroid at every consecutive frame (flow 
direction: x axis). (B) Trajectory of three representative sickle RBCs, showing the 
“stop-and-go” motion. (C) Trajectory of three representative sickle RBCs treated with 
FH (18 nM). (D) Trajectory of three representative sickle RBCs treated with FH 19-20 
segment (18 nM). (E) Absolute values for instantaneous transverse speed expressed 
as mean ± standard deviation (** p < 0.01 vs healthy RBCs). 
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Fig. 5. FH anti-adhesive effect involves P-selectin and Mac-1 pro-adhesive 
molecules.  (A) Sickle cell adhesion after 6 minutes of perfusion on activated or 
non-activated endothelium (+/- TNF-α) pre-coated with either anti-P-selectin antibody 
or anti-Mac1 (CD11b/CD18) antibody. Data shown are representative of other 6 
independent assays with similar results. Wilcoxon test: * indicates the corresponding 
significance. Adhesion is expressed as median values with a minimum-maximum 
range and shown by means of box plots. A value of p<0.05 was considered 
statistically significant. Statistical analysis as in Fig. 2A. (B) Schematic model of the 
beneficial action of Factor H in reducing adhesion of C3-derived opsonins sickle 
RBCs to the TNF-α activated vascular endothelium. C3 split-fragments on 
erythrocyte might favor cell-cell interactions through P-selectin and Mac-1. P-selectin 
might bind RBCs through two different targets iC3b and/or sialic acid; in contrast, 
Mac-1 targets only iC3b deposit on sickle RBCs as more selective interaction. FH 
and FH19-20 segment normalized the transit of sickle RBCs across the TNF-α 
activated vascular endothelial surface, abolishing the “stop-and-go” behavior of the 
sickle RBCs. This effect positively affected (shortened) the transit time of sickle 
RBCs, reducing the likelihood of the RBCs to sickle during their transit of the 
microcirculation.  
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SUPPLEMENTAL METHODS 
 
Evaluation of C5b-9 complement deposition on fixed skin biopsy 
Immunofluorescent staining assay. Paraffin-embedded tissue blocks were 
cut into 2 to 3 μm sections and mounted on adhesion microscope glass slides. After 
the sections were dewaxed and rehydrated. Antigen retrieval was performed in 
prewarmed citrate buffer (pH 6, at 95°C) for 30 minutes. The sections were cooled to 
room temperature and then incubated with a protein-blocking serum free solution for 
15 minutes at room temperature (RT) to block non-specific binding. In healthy 
controls, we stained dermal vessels in serial sections by anti-CD31 as an endothelial 
marker (mouse monoclonal antibody at 1: 50 dilution, Clone JC70A, Dako, Denmark; 
green fluorescence) and C5b9 (anti-human SC5b-9 at 1:100 dilution; Quidel, San 
Diego, CA; orange fluorescence) staining in healthy controls (Figure 1SA). Since 
Sprott et al. previously reported C5b9 deposition to be detectable only in the vessel 
walls of pathologic skin with no involvement of other cutaneous compartments, we 
also analyzed anti-C5b9 staining in skin biopsies from SCD patients (32, 33). Slides 
were then incubated with the corresponding Alexa 488-conjugated antibody or Alexa 
546-coniugated antibody (1:800; INVITROGEN Molecular Probes). Nuclei were 
stained with Prolong Gold antifade reagent with DAPI (INVITROGEN Molecular 
Probes, blue staining). Slides were examined with an Olympus BX61 microscope. 
Immunohistochemical staining assay. Paraffin-embedded tissue blocks 
were cut into 2-3 μm sections and mounted on adhesion microscope glass slides. 
For immunohistochemical staining, sections were stained in an auto-stainer Leica 
Bond System with anti-C5b9 (AbCam clone aE11) and CD31(mouse monoclonal 
antibody at 1: 50 dilution, Clone JC70A, Dako, Denmark) as previously reported (34).  
Measurements of phosphatidylserine+ and C3d+ RBCs 
The deposition of C3-derived opsonins (i.e. C3b, iC3b, C3dg) on RBCs was 
measured by flowcytometry using an antibody (monoclonal antibody anti C3 - EIA 
Quidel Corp., San Diego, CA; USA) recognizing the C3d fragment and is reported as 
C3d+ cells (11, 12). In brief, RBCs were obtained from fresh peripheral blood after 
centrifugation and three washings in saline buffer; washed RBCs were resuspended 
in saline at approximately at the concentration of 104 RBCs/μL, and then incubated 
with a phycoerythrin (PE)–conjugated anti-CD59 (59PE Valter Occhiena) diluted 
1:10, and with a fluorescein isothiocyanate (FITC)–conjugated anti-C3 polyclonal 
 6 
antibody (Ab14396 Abcam; a 1:20 working solution from the original tube was used 
at a final dilution of 1:50). Samples were incubated at RT for 1 hour, and then 
analyzed with a FACScan cytometer (Becton Dickinson Italia), after dilution with 10 
volumes of saline (or FACS flow, Becton Dickinson Italia). 
Red blood cell adhesion assay 
Blood samples were collected in ACD anticoagulant and RBCs were 
separated from the plasma, washed in phosphate buffer (PBS), re-suspended at 2% 
haematocrit (Hct) in RMPI serum-free Roswell Park Memorial Institute medium 
(RPMI, Gibco) medium (containing 1% bovine serum albumin, Sigma Aldrich), and 
then were incubated with 70uM Carboxyfluorescein Diacetate Succinimidyl Ester 
(CFDA-S; Life Technology)  for 1 hour at 37°C. Labelled RBCs first were washed 
three times and then were re-suspended at 0.2% Hct in serum-free RMPI medium, 
containing 1% bovine serum albumin. The RBCs suspension, depleted of white 
blood cells (WBC), was then incubated  for 10 minutes at 37°C with either full-length 
FH or its recombinant segments encompassing domains 6-8 (FH6-8) or 19-20 
(FH19-20), which were produced as previously described (41), or with calcium and 
magnesium-free PBS as a negative control, then perfused to generate a wall shear 
stress of 30 sec-1. Prior to the adhesion assays, haemolysis was determined using 
CN-FREE HGB reagent on  ADVIA 120/2120 system (Siemens); no hemolysis was 
detected after the incubation time, prior to the adhesion assay (data not shown). A 
monolayer of immortalized endothelial cells (EA 926.hy cell line, ATCC® CRL-2922™) 
was grown at the bottom of the perfusion chamber, then incubated with TNFα 
(Sigma Aldrich-Merk KGaA, Darmstadt, Germany) for 4 hours at 37°C in 5% CO2 in 
serum free medium. In preliminary experiments, primary TNFα-activated endothelial 
cells (HUVEC, ATCC® CRL-1730™) were used in the presence or absence of Factor 
H, and the results obtained were similar to those obtained with immortalized cells. 
RBC suspension perfused in the flow chamber was monitored for 10 minutes, during 
which time 10 different locations along a line oriented to the flow were examined 
every 3 min. in order to study cell adhesion and aggregation. To discriminate and 
count cells on flow we set-up a new software called Cell Counter-BL The software 
exploits the characteristics of long exposure photographs, in which the moving parts 
tend to disappear, while the adhering cells are imprinted on the image. Blocking 
antibodies against P-selectin (Anti-CD62P [AK4]; Abcam) or Mac-1 (CD11b/ CD18 
[CBRM1/5]; Biolegend) were used at final concentration of 25 ug/ml.  
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Immortalized human endothelial cell EA926.hy were grown as monolayer in DMEM 
10% FCS medium. This cell line was obtained from HUVEC (Human Umbelical Vein 
endothelial cell) cell line and maintain key characteristic of HUVEC.  Endothelial cell 
passage was accomplished with trypsinization, as required. For flow experiments EA 
926.hy cells were plated at a density sufficient to reach confluence. EA 926.hy cells 
were treated with 20nM TNFα for 4hours at 37 °C to create a cytokine mediated 
activation mimicking inflammatory state, non-activated endothelium was used as a 
control. In some experiment HUVEC cells were used as a control to compared and 
confirm results obtained with immortalized endothelial cells.  
Flow chamber position and optical area of analysis 
The flow chamber was positioned on the stage of an inverted microscope equipped 
with epifluorescent illumination (Diaphot-TMD; Nikon Instech, Shinagawa-ku, Japan), 
an intensified CCD videocamera (C-2400-87; Hamamatsu Photonics, Shizuoka, 
Japan), and appropriate filters. The total area of an optical field corresponded to 
approximately 0.007 mm2. Blood cells were aspirated through the chamber with a 
syringe pump (Harvard Apparatus, Hollistone, MA) at a flow rate calculated to obtain 
the desired wall shear rate at the inlet. Experiments were recorded in real time on 
videotape at the rate of 25 frames/s, which resulted in a time resolution of 0.04 s.  
Quantification of red blood cell adhesion: Cell Counter-BL Software 
It is based on computational sum of frames that constitute a field of view. This is then 
divided by the number of frames obtaining an effect similar to a long exposure. The 
first image has non-homogeneous light background because of presence of a bright 
spot. For this reason, it was necessary to perform a background subtraction by 
calculation of the dynamic background on each image. An interpolating function of 
degree 4 was applied for all rows of the image. For the part of the cell count has 
exploited an algorithm known in the literature (http://en.wikipedia.org/wiki/Flood_fill). 
Development of an algorithm to determine RBC transit and flux trajectory 
Experiments were performed on an inverted fluorescence microscope and 
recorded in real time on videotape at the rate of 25 frames/second, resulting in a 
time resolution of 0.04 sec. Endothelial cells activated with TNFα were grown on the 
coverslip of the flow chamber and experiments were run as reported above. Selected 
video sequences were digitalized using VirtualDub software (www.virtualdub.org; 
open source software). Image analysis was accomplished using the Volocity 
software (Perkin Elmer) and by programming codes in MatLab R2014b (The 
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MathWorks). The trajectory of each individual RBC was followed with Volocity from 
first appearance of the particle in the field of view to its disappearance, considering 
the field in question as a fixed region of 125 x 375 pixels, which was equivalent to an 
area of 50 x 150 µm, (using a conversion factor of 0.4 µm/pixel).  
For each RBC, fixing the x axis as the flow direction and the y axis as its 
perpendicular coordinate, the absolute values for instantaneous speed (| v | t) and for 
the instantaneous transverse speed (| vy | t, both in µm/second) were quantified with 
MatLab, according to their definition, as: 
 
| v | t = sqrt (vx 2 + vy 2) t = sqrt ((Δx / Δt) 2 + (Δy / Δt) 2) t 
 
| vy | t = | Δy / Δt | t = | (y t - y t-1) / (t - (t-1)) | 
 
where t is the time instant in which the calculation was performed and t-1 the 
preceding instant before. All computational analyses were performed frame by 
frame, for each observation time.  
P-selectin and Mac-1 expression in vitro in vascular endothelial cells  
Immunoblot analyses. Vascular endothelial cells were lysed with iced lysis buffer 
(LB containing: 150mMNaCl, 25mM bicine, 0.1% SDS, 2% Triton X-100, 1mM 
EDTA, protease inhibitor cocktail tablets [Roche] and 1mMNa3VO4 final 
concentration) followed by centrifugation at 4°C for 30 min at 12,000 g. Proteins 
were quantified and analyzed by mono-dimensional SDS polyacrylamide gel 
electrophoresis. Gels were transferred to nitrocellulose membranes for immunoblot 
analysis with specific antibodies: anti-P-Selectin (both from BD, Biosciences, San 
Jose, CA, USA)). Anti-tubulin was used as a loading control (Developmental Studies 
Hybridoma Bank [DSHB], Department of Biology, University of Iowa, Iowa City, IA, 
USA). Secondary donkey anti-rabbit IgG and HRP-conjugated were from GE 
Healthcare Life Sciences. Blots were developed by using the Luminata Forte 
Chemiluminescent HRP Substrate from Merck Millipore (Darmstadt, Germany), and 
images were acquired with an Image Quant Las Mini 4000 Digital Imaging System 
(GE Healthcare). Densitometric analyses were performed by using an ImageQuant 
TL software (GE Healthcare Life Sciences) (42).  
Cytofluorimetric analysis. EA926.hy endothelial cells were seeded on a cover-
sleep in order to obtain a cell monolayer. Endothelial cells were activated with 
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20ng/ml of TNFα in serum free medium for 4 hours before and then they were 
analyzed for surface CD11b (with anti MAC-1 APC, ICRF44 Biolegend). As controls, 
untreated cells and an isotypic antibody (MOPC-21 mouse IgG1k; Biolegend) were 
used. Analysis was performed with a FACScan cytometer (FORTESSA, Becton 
Dickinson). 
 
 
 
 
